By Kyle LaHucik,Annalee Armstrong,Max Bayer
Russia's invasion of Ukraine could impact clinical studies as there are more than 250 trials with at least one site in the Eastern European nation, according to ClinicalTrials.gov. Karuna Therapeutics noted one of its schizophrenia trials has no clear timeline because 10 of 19 sites are in Ukraine.
read more
By Paige Minemyer
The Department of Justice has filed suit to intervene in UnitedHealth Group's acquisition of Change Healthcare, just days shy of the company's planned consummation date of Feb. 27.
read more
By Andrea Park
Even without the rollout of the latest model of its tubeless insulin pump system—the Omnipod 5, which was originally poised to receive FDA clearance early last year but didn’t secure the agency’s OK until last month—Insulet still broke new ground in its 2021 earnings.
read more
By Fraiser Kansteiner
This year, Moderna expects revenue from sales of its mRNA-based COVID-19 vaccine to clock in at around $22 billion. The company has locked up advanced purchase agreements worth $19 billion, with additional signed options valued at roughly $3 billion, the company said Thursday.
read more
By Kyle LaHucik
AbbVie is ditching work on all the alpha V beta 6 (αvβ6) inhibitors that it paid $20 million to license from Morphic Therapeutic in 2020. The Big Pharma is culling the work because of a suspected on-target "safety signal" from preclinical testing.
read more
By Andrea Park
According to the SEC, from at least 1995 until 2019, Baxter converted its internal foreign transactions, assets and liabilities into U.S. dollars on its financial statements using a method that “was not in accordance with U.S. GAAP or generally accepted accounting principles.”
read more
By Dave Muoio
The federal regulator and Rhode Island's attorney general previously agreed that the deal would lead to "extraordinary" market power, likely raising prices and reducing the quality of care across the state and into some nearby Massachusetts communities.
read more
By Angus Liu
As Sanofi and GlaxoSmithKline's COVID-19 vaccine finally heads to regulators, another shot using GSK’s pandemic adjuvant has taken home its first global approval.
read more
By Andrea Park
Though still hard at work detangling the biology of patient-specific drug response, Scipher Medicine has already solved another very important piece of the startup puzzle: fundraising.
read more
By Nick Paul Taylor
Merck has dumped Moderna’s mutant KRAS vaccine mRNA-5671. The action, which comes shortly after Merck closed enrollment in a phase 1 trial, leaves Moderna pondering the next steps for the program.
read more
By Kevin Dunleavy
Ahead of schedule, Merck KGaA’s subsidiary in the United States, MilliporeSigma, has completed its acquisition of Indianapolis-based Exelead, following regulatory approvals and other clearances, for $780 million. The company will pour an additional $557 million into Exelead over the next 10 years. The deal is part of Merck KGaA’s effort to expand into the booming mRNA market.
read more
By Max Bayer
Less than four months after finalizing its spinoff from bluebird bio, leaders of 2seventy bio say their pipeline's current success stories are not the bar, including FDA-approved Abecma. Instead, those at the helm believe the company's future will be defined by the science it's now chasing.
read more
By Rebecca Torrence
Virtual chronic care management company Omada Health hit unicorn status with a $192 million series E round led by Fidelity, the company announced Wednesday.
read more
